---
title: "Bristol-Myers Squibb Company (CELG.RT.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/CELG.RT.US.md"
symbol: "CELG.RT.US"
name: "Bristol-Myers Squibb Company"
industry: "Oncology Biopharmaceuticals"
datetime: "2026-05-20T14:41:48.579Z"
locales:
  - [en](https://longbridge.com/en/quote/CELG.RT.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/CELG.RT.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/CELG.RT.US.md)
---

# Bristol-Myers Squibb Company (CELG.RT.US)

## Company Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia.

| Item | Detail |
|------|--------|
| Industry | Oncology Biopharmaceuticals |
| Exchange | US Market |
| Website | [www.bms.com](https://www.bms.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/CELG.RT.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/CELG.RT.US/norm.md)
- [Related News](https://longbridge.com/en/quote/CELG.RT.US/news.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**